

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED**

**招商局中國基金有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 133)**

## **FURTHER INVESTMENT IN XUNFEI HEALTHCARE**

Reference is made to the announcement of China Merchants China Direct Investments Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) dated 30 December 2019 in relation to the acquisition of 3% of the ordinary shares of 訊飛醫療科技股份有限公司(Xunfei Healthcare Technology Co., Ltd., “**Xunfei Healthcare**”, its present name) by Shenzhen Tian Zheng Investment Co., Ltd. (“**Tian Zheng**”), a wholly-owned subsidiary of the Company, at the consideration of RMB60 million (the “**First Investment**”). In addition, the Company made an announcement on 3 December 2021 that Tian Zheng acquired a further 0.7143% of the ordinary shares of Xunfei Healthcare at the consideration of RMB50 million (the “**Additional Investment**”). As a result of the First Investment and the Additional Investment, Tian Zheng has invested a cumulative total of RMB110 million in Xunfei Healthcare and held a 3.426% interest in Xunfei Healthcare prior to its listing.

The Company announces that Star Group Limited (“**Star Group**”), a wholly-owned subsidiary of the Company, entered into a cornerstone investment agreement dated 16 December 2024 in relation to Xunfei Healthcare’s global offering, pursuant to which Star Group subscribed for a certain number of H shares of Xunfei Healthcare at the offer price with an amount of HKD28 million. According to the announcement on allotment results of Xunfei Healthcare dated 27 December 2024, Star Group was allocated 338,150 H shares, representing 0.28% of the total issued share capital of Xunfei Healthcare after its global offering. Together with the First Investment and the Additional Investment, the Group has cumulatively invested an equivalent amount of approximately RMB136 million in Xunfei Healthcare and holds a 3.506% interest in Xunfei Healthcare as at the date of this announcement, i.e. a total of 4,238,150 H Shares (of which 3,900,000 shares are subject to a lock-up period of 12 months and 338,150 shares are subject to a lock-up period of 6 months).

## **Information on Xunfei Healthcare**

Xunfei Healthcare was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on 30 December 2024 (Stock Code: 2506). According to the global offering document of Xunfei Healthcare, it is an AI-empowered healthcare solution provider, offering products and solutions that support a range of healthcare services, ranging from health risk warnings, early screening, auxiliary diagnosis and treatment as well as treatment effect evaluation to post-discharge management and chronic disease management. Xunfei Healthcare has independently developed AI technologies that underpin its products and solutions. Specifically, Xunfei Healthcare offers (i) Primary Healthcare (“**PHC**”) Services to assist PHC doctors in improving their service capabilities and enable more effective monitoring by regional healthcare administrators; (ii) Hospital Services to improve the operational efficiency of hospitals and doctors; (iii) Patient Services to enhance the convenience and quality of healthcare services received by patients, including outpatients, inpatients residing in medical institutions and discharged inpatients at home, as well as other individual customers; and (iv) Regional Healthcare Solutions to assist regional healthcare administrators in data-driven integrated management as well as efficient deployment of health insurance funds. Xunfei Healthcare ranked first in the healthcare AI industry in terms of revenue in China with a market share of 5.9% in 2023, according to an independent market research and consulting company (Frost & Sullivan).

For and on behalf of  
CHINA MERCHANTS CHINA DIRECT  
INVESTMENTS LIMITED  
**WANG Xiaoding**  
*Director*

Hong Kong, 23 January 2025

*As at the date hereof, the Executive Directors of the Company are Mr. WANG Xiaoding and Ms. KAN Ka Yee, Elizabeth; the Non-executive Directors are Mr. ZHOU Xing, Mr. ZHANG Rizhong, Mr. KE Shifeng and Mr. TSE Yue Kit; and the Independent Non-executive Directors are Mr. TSANG Wah Kwong, Dr. LI Fang, Dr. GONG Shaolin, Mr. Michael Charles VITERI and Mr. ZHU Qi.*